Prot #ABX464-105: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects with Moderately to Severely Active Ulcerative Colitis (ABTECT-1)

Project: Research project

Project Details

StatusActive
Effective start/end date11/19/24 → 11/19/27

Funding

  • Quintiles, Inc. (Prot #ABX464-105 // Prot #ABX464-105)
  • Abivax (Prot #ABX464-105 // Prot #ABX464-105)